Cape Verde vs Tunisia: HIV/AIDS deaths averted by antiretroviral therapy
HIV/AIDS deaths averted by antiretroviral therapy over time
- Cape Verde
- Tunisia
How they compare
Tunisia currently reports 198.78 deaths against 176.27 deaths in Cape Verde, a difference of 22.51 deaths.
That makes Tunisia's figure about 1.1 times Cape Verde's.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Tunisia ahead.
Cape Verde ranks 111th and Tunisia ranks 110th of 157 countries.
Across the 4 decades both report, Cape Verde averaged higher in 2 and Tunisia in 1.
Head to head by decade
| Decade | Cape Verde | Tunisia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 37.38 deaths | 23.7 deaths | 13.68 deaths | Cape Verde |
| 2010s | 125.26 deaths | 81.37 deaths | 43.88 deaths | Cape Verde |
| 2020s | 164.69 deaths | 164.95 deaths | 0.259 deaths | Tunisia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Cape Verde or Tunisia?
- Tunisia, at 198.78 deaths against 176.27 deaths in Cape Verde as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Cape Verde and Tunisia?
- 22.51 deaths, with Tunisia ahead.
- How many years of comparable data are there for Cape Verde and Tunisia?
- 35 years are reported by both, from 1990 to 2024.
- How do Cape Verde and Tunisia rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Cape Verde ranks 111th and Tunisia ranks 110th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.